BTAI vs. EPR

In the year-to-date period, BTAI achieves a -77.94% return, which is significantly lower than EPR's 30.17% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for BioXcel Therapeutics, Inc. (BTAI) and EPR Properties (EPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BTAI Sharpe Ratio is -0.67, which is lower than the EPR Sharpe Ratio of 2.13. The chart below compares the historical Sharpe Ratios of BTAI and EPR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BTAI has not paid dividends to shareholders, while EPR's dividend yield for the trailing twelve months is around 6.16%.

The maximum BTAI drawdown since its inception was -99.89%, which is greater than EPR's maximum drawdown of -82.02%. Use the drawdown chart below to compare losses from any high point for BTAI and EPR.

BioXcel Therapeutics, Inc. (BTAI) has a higher volatility of 20.66% compared to EPR Properties (EPR) at 6.11%. This indicates that BTAI's price experiences larger fluctuations and is considered to be riskier than EPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between BioXcel Therapeutics, Inc. and EPR Properties. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.